Showing results (391-400 of 793) with videos related to

Sort By:
Pageof 80
Haematologica|June 30, 2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myelomaJesús F San-Miguel, Maria-Asunción Echeveste Gutierrez, Ivan Špicka, et al.
The Lancet. Oncology|September 24, 2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind studyMeletios Dimopoulos, David S Siegel, Sagar Lonial, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2015
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or LymphomaJatin J Shah, Andrzej J Jakubowiak, Owen A O'Connor, et al.
NPJ Vaccines|October 28, 2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Research Square|October 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
The Journal of Clinical Investigation|August 27, 2019
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradationChaoyun Pan, Jaemoo Chun, Dan Li, et al.
Nucleic Acids Research|January 31, 2016
Gene integrated set profile analysis: a context-based approach for inferring biological endpointsJeanne Kowalski, Bhakti Dwivedi, Scott Newman, et al.
British Journal of Haematology|August 8, 2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphomaJonathon B Cohen, Jeffrey M Switchenko, Jean L Koff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialMeletios A Dimopoulos, Ivan Špička, Hang Quach, et al.
Pageof 80